AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

The C-reactive Protein (CRP) Point of Care Testing (POCT) Implementation to Adult Patients Presenting With Symptoms of the Acute Respiratory Tract Infection (ARTI) in Eight Primary Health Care (PHC) in Jakarta.

RecruitingNAAges 18 Years - anyAllOxford University Clinical Research Unit Indonesia
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Antimicrobial resistance (AMR) has emerged as one of the most pressing global health challenges of the 21st century, particularly Indonesia is projected to be among the five nations globally with the highest percentage increase in antimicrobial consumption by 2030. Primary care settings represent the most critical implementation point for addressing inappropriate antibiotic use. ARTI constitutes the most common indication for antibiotic prescribing in primary care, yet much of this prescribing is inappropriate. The high frequency of inappropriate antibiotic prescribing for ARTI is particularly problematic because most of these infections are viral in nature and resolve spontaneously without antibiotic treatment. Studies across the Asia-Pacific region, including Indonesia, have documented antibiotic prescribing rates for upper respiratory tract infections ranging from 47% to 85%, indicati

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: 1. Adults aged โ‰ฅ18 years. 2. Presenting to the PHC site for the first consultation of the current episode of Acute-Respiratory Tract Infections (ARTI). 3. Reporting at least one of the following symptoms or clinical signs within the past 5 days: cough, rhinitis (e.g., sneezing, nasal congestion, or runny nose), pharyngitis (e.g., sore throat), shortness of breath, wheezing, chest pain, abnormal lung sounds on auscultation. Exclusion Criteria: 1. Presenting with severe illness requiring referral to a higher-level healthcare facility (e.g., hospital). 2. Having known immunosuppression or chronic conditions, including but not limited to: HIV infection; chronic liver disease; history of malignancy; long-term use of systemic corticosteroids or other immunosuppressive therapies, as assessed by the healthcare worker or study team. 3. Having taken antibiotics prior to the visit to the primary health center.
๐Ÿ’Š

What it tests

  • Implementation group
๐Ÿ“

Where

8 sites
Cengkareng Public Health Center
Jakarta, Indonesia
Kebayoran Lama Public Health Center
Jakarta, Indonesia
Pulo Gadung Public Health Center
Jakarta, Indonesia
Jatinegara Public Health Center
Jakarta, Indonesia
Duren Sawit Public Health Center
Jakarta, Indonesia
Cakung Public Health Center
Jakarta, Indonesia
Cilincing Public Health Center
Jakarta, Indonesia
Koja Public Health Center
Jakarta, Indonesia
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy